Needham Maintains Buy on Revolution Medicines, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $36 to $46.
April 12, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines and raises the price target from $36 to $46.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100